Gynecological Cancer Drugs Market 2020: In-Depth Analysis, Applications, Key End-Users Forecasts To 2028

-
Gynecological Cancer Drugs
Gynecological Cancer Drugs

Gynecological Cancer Drugs are defined as the uncontrollable growth and spread of abnormal cells in the female reproductive organs, including the cervix, uterus, ovaries, vagina, and vulva. Furthermore, one of the risk factors for gynaecological cancer is infection with the virus known as HPV, or Human Papillomavirus. Furthermore, factors such as infertility, obesity, mutations, early menstruation or late menopause can all lead to gynaecological cancer.

To meet the growing Demand For Gynecological Cancer Drugs, pharmaceutical and biotech companies are focusing on research and development in order to bring new gynecological cancer drugs to market. Furthermore, some generic drug manufacturers are focusing on producing patent-expired drugs in generic form for the treatment of this cancer. 

For example, Dr Reddy's Laboratories, based in India, received US Food and Drug Administration approval in May 2017 to market Doxorubicin Hydrochloride Liposome injection in the United States. This Doxorubicin Hydrochloride Liposome is a therapeutic equivalent generic version of Doxil, a chemotherapy drug used to treat cancers like ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.

The rising prevalence of Gynecological Cancer Drugs is expected to be a major driver of market growth. Endometrium cancer, a type of cervical cancer, is the most common cancer of the female reproductive organs, according to the American Cancer Society. Furthermore, it is estimated that 47,130 new cases of endometrial cancer will be diagnosed in the United States in 2012, with approximately 8,010 women dying from the disease. 

Furthermore, according to the American Cancer Society, ovarian cancer is the eighth most common cancer among women, and it was estimated in 2012 that approximately 22,280 new cases of ovarian cancer will be diagnosed in the United States, which is expected to support growth in the Gynecological Cancer Drugs

Furthermore, in 2017, the US Food and Drug Administration approved Zejula (niraparib), a targeted therapy drug for women with certain types of the ovarian, fallopian tube, or peritoneal cancer. It is also approved for women who have had a relapse of cancer after undergoing chemotherapy. As of March 2018, the American Cancer Society had funded approximately 22 grants for cervical cancer, totaling approximately US$ 9.3 million. The funding value is offered to a single or group of research projects that include a specific type of cancer or cancer area.

Comments

Post a Comment

Popular posts from this blog

Security Robot Market to Reach US$ 11.8 Billion by 2022

-
Image
Security Robot Market The Global Security Robot Market is estimated to be valued at US$ 11.8 billion in 2022 and is expected to exhibit a CAGR of 12.87% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Security robots are rapidly gaining traction due to their ability to enhance security and surveillance in various industries. These robots offer advantages such as round-the-clock monitoring, real-time video monitoring, and quick response to potential threats. The increasing need for advanced security measures to prevent theft, vandalism, and unauthorized access is driving the demand for security robots. These robots are widely used in industries such as retail, healthcare, transportation, and manufacturing to ensure the safety of assets and individuals. The market is expected to witness significant growth due to the rising security concerns and advancements in robotic technologies. Market Key Trends: One ke
Read more

Intravenous Fluid Therapy is the Fastest Growing Segment Fueling the Growth of Intravenous Solutions Market

-
Image
Intravenous Solutions Market The global Intravenous Solutions Market is estimated to be valued at US$ 577,228 bn or Million in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Intravenous solutions are fluids administered through a vein via a needle or catheter. They are often used to provide essential nutrients, medications, or fluids to patients. Common uses include rehydration, correcting electrolyte imbalances, and ensuring nutrition is delivered for patients who cannot eat or absorb nutrients through the digestive system. Market key trends: One of the major trends in the intravenous solutions market is the increasing use of intravenous fluid therapy. Intravenous fluid therapy involves the administration of aqueous solutions containing electrolytes, sugars, and medications through an intravenous catheter. It is widely used for rehydration, maintenance of f
Read more

Global Report on LED Driver Market for the Forecast Period 2023-2030

-
Image
LED Driver Market The LED Driver Market has been growing rapidly over the past few years, driven by the increasing demand for energy-efficient lighting solutions across residential, commercial, and industrial sectors. LED (light-emitting diode) lighting technology has several advantages over traditional lighting solutions such as incandescent and fluorescent lights, including longer lifespan, lower energy consumption, and lower maintenance costs. However, to power and control LED lights, an LED driver is required. The LED Driver Market was valued at USD 7.7 billion in 2020 and is expected to reach USD 10.5 billion by 2025, at a CAGR of 6.4% during the forecast period. LED drivers are electronic devices that regulate the power supply to LED lights. They convert AC voltage from a power source to DC voltage suitable for LEDs, and also provide the necessary current and voltage regulation to ensure proper functioning of the LED lights. LED drivers can be either constant current or constant
Read more